AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Plasma Oxytocin Response to Oral Estrogens in Healthy Controls and AVP-Deficiency

RecruitingNAAges 18 Years - 50 YearsAllUniversity Hospital, Basel, Switzerland
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The PHOENIX study aims to investigate whether oral estradiol valerate (EV) and ethinylestradiol (EE) can stimulate oxytocin (OXT) and neurophysin-1 (NP-1) release in humans. The goal is to assess their potential as a safe diagnostic stimulation test for oxytocin deficiency, particularly in patients with arginine vasopressin (AVP) deficiency.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: Part 1 1. Adult healthy controls 2. No medication (including hormonal contraception) 3. Female patients (except post-menopausal): regular cycle (21-35 days of duration) in the last 6 months Part 2 1. Confirmed diagnosis of AVP-Deficiency 2. Age โ‰ฅ 18 years 3. Female patients (except post-menopausal): regular cycle (21-35 days of duration) in the last 6 months or in the case of hormone replacement therapy, with a 1-week pause from the respective treatment Exclusion Criteria: Part 1 1. Participation in a trial with investigational drugs within 30 days 2. BMI \>30 3. Age \>50 4. Illicit substance use (except for cannabis) during the last 30 days 5. Consumption of alcoholic beverages \>15 drinks/week 6. Tobacco smoking \>10 cigarettes/day 7. Pregnancy and breastfeeding 8. Hormonal contraception 9. Migraine with and without aura 10. Any cardiometabolic, cardiovascular, and hematological diseases (including deep vein thrombosis/pulmonary embolism and thrombophilia (DVT/PE)) 11. Active liver dysfunction or alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) levels 2.5 times above the normal range 12. Diagnosed chronic kidney disease (CKD) \> grade III (GRF \< 30ml/min) Part 2 1. Participation in a trial with investigational drugs within 30 days 2. BMI \>30 3. Age \>50 4. Illicit substance use (except for cannabis) during the last 30 days 5. Consumption of alcoholic beverages \>15 drinks/week 6. Tobacco smoking \>10 cigarettes/day 7. Pregnancy and breastfeeding 8. Hormonal contraception 9. Migraine with and without aura 10. Any cardiometabolic, cardiovascular, and hematological diseases (including DVT/PE and Thrombophilia) 11. Active liver dysfunction or alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) levels 2.5 times above the normal range 12. Diagnosed CKD \> grade III (GRF \< 30ml/min)
๐Ÿ’Š

What it tests

  • estradiol valerate
  • esthinylestradiol
๐Ÿ“

Where

1 site
University Hospital Basel
Basel, Switzerland
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy